HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
Weijun Gu, Lihui Zhang, Ling Li, Dong Wei, Qifu Li, Yicen Zong, Zi Ye, Chang Shu, Tingyan Zhong, Yiming Mu · 2026
Read HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial by Weijun Gu, Lihui Zhang, Ling Li, Dong Wei, Qifu Li, Yicen Zong, Zi Ye, Chang Shu, Tingyan Zhong, Yiming Mu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13443196.txt.
Description
Weijun Gu and colleagues test a daily pill, HRS-7535, for weight loss in Chinese adults with obesity in a 2026 trial. The pill wakes the GLP-1 receptor, a gut signal that curbs hunger. Across 29 centers, 235 adults without diabetes took one of four doses or a dummy pill for 26 weeks.
Weight fell with dose in clear steps across the arms. The top dose gave a mean change of minus 9.36 percent of body weight by week 26, against minus 2.50 percent for the dummy arm. Mid doses landed between those marks, with gains past the dummy arm from 60 mg up. Gut side effects led the harm list and clustered in dose-climb weeks. Most harms stayed mild or mid-grade in this phase 2 run.
Catalog record
| CREATOR | Weijun Gu, Lihui Zhang, Ling Li, Dong Wei, Qifu Li, Yicen Zong, Zi Ye, Chang Shu, Tingyan Zhong, Yiming Mu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72947 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |